Categories
STUDY PURPOSE

FASTEST GROWING PHARMA COMPANY FOR LONG TERM INVESTORS.

Small Cap Company with Good Returns For Long Term Investors Expecting in Big Gains .

STUDY PURPOSES ONLY .

WANBURY LTD Now Trading at CMP 90.20 .

Target : 108 – 125 to 160++

52 WEEKS HIGH /LOW : 114.70/16.05.

Time Frame : 6 months to 3 Years .

Wanbury Ltd is the fastest growing pharma company with a Compounded Annual Growth Rate(CAGR) of 68% over the last 6 years.

Wanbury Limited, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.

Wanbury’s major trust area lies in Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India Formulation presence.

Wanbury has a basket of over 13 API products.

It is the largest manufacturer of Metformin with over 8500 tons per year.

Wanbury exports to over 50 countries, 65% of which comprises of regulated markets.

Has two US-FDA approved multi-product API facilities and one plant under operation for semi-regulated
markets.

Has been the preferred supplier to some of the top five generic players of the world.

It has the larger customer base in Europe & US for Tramadol & Setraline (API).

Pan-India presence in ethical formulations with a portfolio of close to 70 brands.

Strong presence in gynecology, orthopedics, heamatinics, anti-diabetic, neutraceuticals, gastro intestinal,
stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics and general practitioner.

Profit Enhancement Program (PEP):
PEP programs are carried out every year to improve profits, figuring out alternative routes of manufacturing products, reducing cycle times, increasing per capita productivity per person, increasing per capita per liter output, cost reduction, wastages etc. is continuously carried out by separate task force in consultation with R&D along with SBUs, Divisions, and plant heads.

Disclaimer: I am Not a SEBI REGISTERED ANALYST. This Website & Its Owner, Creator & Contributor is Neither a Research Analyst nor an Investment Advisor and Expressing Option Only as an Investor in Indian Equities. All trading strategies are used at your own risk.

He/ She are Not Responsible for any Loss a Rising out of any Information, Post or Opinion Appearing on this Website. Investors are advised to do Own Due Diligence or Consult Financial Consultant before acting on Such Information. Author of this Website not providing any Paid Service and not Sending Bulk mails/SMS to Anyone.

Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted. Investment/Trading in securities Market is subject to market risk.

This is my personal thoughts on this company and not at all a buy recommendation. Do own due diligence /consult a SEBI registered advisor before any action.

Leave a Reply